Top Markets
#1 Prom Prom +36.01%
#2 QuantixAI QuantixAI +31.15%
#3 MowCat MowCat +27.85%
#4 UnifAI Network UnifAI Network +23.33%
#5 Tutorial Tutorial +19.31%
#6 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +18.53%
#7 Pons Pons +17.42%
#8 Versatize Coin Versatize Coin +16.65%
#9 Derive Derive +13.93%
#10 GEKKO GEKKO +13.35%
Coin of the day
Prom Prom
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Captor Therapeutics Spolka Akcyjna Captor Therapeutics Spolka Akcyjna

Captor Therapeutics Spolka Akcyjna

CTX
Rang in Aktien #20515
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the... Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.
Aktienkurs
$20.38
Marktkapitalisierung
$129.09M
Veränderung (1 Tag)
-0.82%
Veränderung (1 Jahr)
80.91%
Land
PL
Handel Captor Therapeutics Spolka Akcyjna (CTX)

Kategorie

Healthcare
P/B-Verhältnis für Captor Therapeutics Spolka Akcyjna (CTX)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Captor Therapeutics Spolka Akcyjna beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Captor Therapeutics Spolka Akcyjna von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH